Epidarex Capital
VC Fund
Bethesda, United States
Epidarex Capital is a VC fund in Bethesda focused on Biotechnology and Health Care. Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, international corporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.
- Total investments:
- 53
- Last investment:
- Lead investor:
- 45%
- Fund size:
- $145M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Epidarex Capital invests in
Stages Epidarex Capital invests in
Countries Epidarex Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $551k–$8.5M
- Series A
- $2.6M–$40M
- Series B
- $2.4M–$48M
Investment Focus
Industry
- Biotechnology 21 (40%)
- Health Care 14 (26%)
- Therapeutics 13 (25%)
- Medical 7 (13%)
- Life Science 5 (9%)
Stage
- Series A 22 (42%)
- Series B 7 (13%)
- Seed 6 (11%)
- Venture - Series Unknown 3 (6%)
- Series C 1 (2%)
Country
- United Kingdom 18 (34%)
- United States 7 (13%)
- Germany 2 (4%)
- The Netherlands 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Elizabeth Roper
Partner
|
Partner | Total investments: 7 | Find email | |
Peter Finan
Partner
|
Partner | Total investments: 7 | Find email | |
Terri Burke
Venture Partner
|
Venture Partner | Total investments: 1 | Find email | |
|
Kyparissia Sirinakis
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 1 | Find email | |
|
Sinclair Dunlop
Managing Partner
|
Managing Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| RougeTx is a Netherlands-based biotech developing first-in-class small-molecule therapies for vascular diseases caused by pericyte dysfunction. Its lead candidate, RTX-001, targets hereditary haemorrhagic telangiectasia (HHT), an inherited disorder involving fragile blood vessels and recurrent bleeding. | $58M / Series A / Oct 06, 2026 | ||
| Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network. | $45.9M / Series B / Aug 05, 2026 | ||
| RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinoutof Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry | $48M / Series B / Jul 16, 2026 | ||
| Leucid Bio is a pioneering biotech company developing cell therapies for refractory cancers, especially solid tumors. Leucid was founded to translate 20 years of King's College London (King's) research in the CAR-T field and is led by a highly experienced management team with both scientific and commercial expertise. As part ofLeucid's ongoing relationship with King's, it benefits from exclusive access to and resources from the deep scientific, clinical, and manufacturing expertise of Dr. Maher and his academic team of immuno-oncology experts. | $8.9M / Series A / Feb 01, 2025 | ||
| Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. | Jan 27, 2025 | ||
| IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $16.3M / Series B / Sep 09, 2024 | ||
| Ryme Medical is a company that develops therapies aimed at treating individuals suffering from chronic bronchitis and emphysema. The organization focuses on addressing chronic obstructive pulmonary disease by targeting the sympathetic nervous system, mitigating its effects, and alleviating the distress of those who struggle to breathe. Thisapproach allows patients to receive improved treatment and breathe with greater ease. | Series A / Aug 21, 2024 | ||
| Theolytics is a clinical stage biotechnology company harnessing viruses to combat disease. A step-change in the adenoviral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition toadvancing an internal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development. | $23.7M / Venture - Series Unknown / Apr 17, 2024 | ||
| Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs. | $51.4M / Series A / Feb 27, 2024 | ||
| Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life. | $33.1M / Series B / Jan 29, 2024 | ||
| See all 53 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Epidarex Capital invest in?
Epidarex Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 53 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Epidarex Capital invest in?
Epidarex Capital typically joins rounds of $551k–$8.5M at Seed, $2.6M–$40M at Series A and $2.4M–$48M at Series B. These are whole funding-round sizes, not Epidarex Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Epidarex Capital took part in.
How do I contact Epidarex Capital?
Public channels for Epidarex Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Epidarex Capital?
The team at Epidarex Capital includes Elizabeth Roper (Partner), Peter Finan (Partner) and Terri Burke (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
